Biomarkers are widely used in development of drugs. One of the primary processes through which biomarkers are accepted for use in drug development, is the drug approval process. The biomarker is included in the regulatory submission process for drug approval such as Investigational New Drug (IND), Biologics License Disease Indications (BLA), or New Drug Disease Indication (NDA), and are then accepted for use in that specific drug development program. Another process through which biomarkers are accepted for use in drug development is the Biomarker Qualification Program (BQP), which qualifies a biomarker for a particular context of use (COU), independent of a drug approval submission. This pathway is intended for biomarkers that are used in multiple drug development programs. Qualified biomarkers have the potential to offer valuable information that may help during drug development.
Market Dynamics
Factors such as increasing initiatives for development of precision medicine, increasing prevalence of chronic diseases, and increasing demand for development of companion diagnostics, is supporting the growth of global biomarker research services market. For instance, in 2017, National Institutes of Health launched Precision Medicine Initiative (PMI) with an investment of US$ 215 million to accelerate biomedical research and offer clinicians new tools to select therapies that can be used in a more individualized approach with patients. Moreover, potential of biomarkers in disease diagnosis, and in companion diagnostics is expected to boost global biomarker research services market growth. Organizations such as Covance, Inc., Charles River, and others are actively involved in providing biomarker research services.
Key features of the study:
- This report provides in-depth analysis of global biomarker research services market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global biomarker research services market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key companies covered as a part of this study include Noble Life Sciences, Inc., Reprocell Corporation, Coriell Institute, BioIVT, ICON Plc., SRI International, Inc., Charles River Laboratories, Inc., Nordic Bioscience A/S, Proteome Sciences Plc., and Covance Inc. (Laboratory Corporation of America Holdings, Inc.)
- Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global biomarker research services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global biomarker research services market
Detailed Segmentation:
- Global Biomarker Research Services Market, By Service Type:
- Biomarker Research Services
- CDx Research Services
- Global Biomarker Research Services Market, By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- Global Biomarker Research Services Market, By Region:
- North America
- By Service Type:
- Biomarker Research Services
- CDx Research Services
- By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- By Country:
- Europe
- By Service Type:
- Biomarker Research Services
- CDx Research Services
- By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Service Type:
- Biomarker Research Services
- CDx Research Services
- By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Service Type:
- Biomarker Research Services
- CDx Research Services
- By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Service Type:
- Biomarker Research Services
- CDx Research Services
- By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Service Type:
- Biomarker Research Services
- CDx Research Services
- By Disease Indication:
- Oncology
- Cardiovascular Disorder
- Infectious Disease
- Neurological Disorder
- Immunological Disorder
- Others
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Noble Life Sciences, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- REPROCELL Corporation
- Coriell Institute
- BioIVT
- ICON Plc.
- SRI International
- Charles River Laboratories, Inc.
- Nordic Bioscience A/S
- Proteome Sciences Plc.
- Covance Inc. (Laboratory Corporation of America Holdings, Inc.)
“*” marked represents similar segmentation in other categories in the respective section.
